BridgeBio Oncology Therapeutics, Inc. (BBOT) Income Statement
BBOT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBBOT revenue and net income
BBOT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | −31,968.8% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BBOT quarterly EPS vs estimates
BridgeBio Oncology Therapeutics beat the analyst EPS estimate in 1 of the last 4 quarters. Next report: November 11, 2026 (estimate $-0.65).
BBOT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $610,000 | — | — | — | — |
| Gross profit | −$610,000 | — | — | — | — |
| Research & development | $121.2M | $73.1M | $56.3M | — | — |
| Sales, general & admin | $24.6M | $7.8M | $8.5M | $3,520 | $74,326 |
| Total operating expenses | $145.8M | $80.9M | $64.8M | $3,520 | $43,357 |
| Operating income | −$145.8M | −$80.9M | −$64.8M | −$3,520 | −$43,357 |
| Interest income | $11.3M | $6.4M | $72,000 | — | — |
| Income before taxes | −$134.0M | −$74.3M | −$64.7M | −$3,520 | −$43,357 |
| Net income | −$134.0M | −$74.3M | −$64.7M | −$3,520 | −$43,357 |
| EBITDA | −$145.2M | −$80.7M | −$64.7M | −$3,520 | −$43,357 |
| EPS (diluted) | −$101.98 | $0.32 | −$3.16 | $0.00 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Dec '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $186,000 | $194,000 | — | — | — | — | $156,000 | — | — | — | — |
| Gross profit | — | −$186,000 | −$194,000 | — | — | — | — | −$156,000 | — | — | — | — |
| Research & development | $49.2M | $39.8M | $38.1M | $35.1M | $27.4M | $20.6M | $19.5M | $17.9M | $22.5M | $13.2M | — | — |
| Sales, general & admin | $11.0M | $6.4M | $5.3M | $14.1M | $2.7M | $2.5M | $2.3M | $1.8M | $1.4M | $2.3M | — | — |
| Total operating expenses | $60.2M | $46.0M | $43.4M | $49.2M | $30.1M | $23.1M | $21.9M | $19.7M | $23.9M | $15.4M | $41,692 | $3,520 |
| Operating income | −$60.2M | −$46.2M | −$43.4M | −$49.2M | −$30.1M | −$23.1M | −$21.9M | −$19.7M | −$23.9M | −$15.4M | −$41,692 | −$3,520 |
| Interest income | $3.6M | $3.9M | $4.4M | $3.4M | $1.7M | $1.8M | $2.1M | $2.5M | $1.8M | $5,000 | — | — |
| Income before taxes | −$56.5M | −$42.1M | −$38.8M | −$44.8M | −$28.4M | −$22.1M | −$19.7M | −$17.3M | −$21.8M | −$15.4M | −$41,692 | −$3,520 |
| Net income | −$56.5M | −$42.1M | −$38.8M | −$44.8M | −$28.4M | −$22.1M | −$19.7M | −$17.3M | −$21.8M | −$15.4M | −$41,692 | −$3,520 |
| EBITDA | −$56.3M | −$46.0M | −$43.2M | −$49.0M | −$29.9M | −$23.1M | −$21.8M | −$19.6M | −$23.8M | −$15.4M | −$41,692 | −$3,520 |
| EPS (diluted) | −$0.71 | −$526.11 | −$0.49 | −$1.03 | −$50.33 | −$50.13 | $0.08 | $0.10 | $0.09 | $0.05 | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BBOT's financial statements (latest annual report filed March 5, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BBOT financial results
BridgeBio Oncology Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $134.0 million. Diluted earnings per share came to −$101.98.
See the BBOT stock overview for the latest quote and news, or the BBOT chart for price history and technical indicators.
BBOT income statement FAQ
Does BridgeBio Oncology Therapeutics have revenue?
BridgeBio Oncology Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is BridgeBio Oncology Therapeutics profitable?
No. BridgeBio Oncology Therapeutics reported a net loss of $134.0 million in fiscal 2025.
How much does BridgeBio Oncology Therapeutics spend on research and development?
BridgeBio Oncology Therapeutics spent $121.2 million on research and development in fiscal 2025.
What are BridgeBio Oncology Therapeutics's earnings per share?
BridgeBio Oncology Therapeutics earned $-101.98 per diluted share in fiscal 2025, compared with $0.32 a year earlier.
When will BridgeBio Oncology Therapeutics report its next earnings?
BridgeBio Oncology Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 after the market closes.
When does BridgeBio Oncology Therapeutics's fiscal year end?
BridgeBio Oncology Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 5, 2026.